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 Introduction 
 The inhalation of short-acting vasodilator drugs is at-
tractive to treat severe respiratory and cardiac disease: 
They may cause effective dilation of vessels within the 
lungs without affecting vascular tone in the systemic vas-
culature  [1, 2] . Prostacyclin (PGI 2 ) is ubiquitous in the 
human body. Originally, it has been shown to safely, ef-
fectively and selectively dilate pulmonary vessels in ex-
perimental and clinical pulmonary hypertension of vari-
ous origins  [3–6] . Finally, PGI 2  and its analogs, epopros-
tenol (EPO) and the longer acting iloprost (ILO), have 
been shown to improve pulmonary hemodynamics, right 
heart function, and exercise capacity in patients with pri-
mary pulmonary hypertension  [4, 7] . So far, investigators 
have attributed the positive effects of inhaled PGI 2 -ana-
logs mainly to the reduction in right ventricular afterload 
and – to some extent – of preload, as well. 
 However, a reduction of afterload alone may not suf-
fi ciently explain the pronounced improvement in stroke 
volume, observed after administration of PGI 2 -analogs 
when compared to other pure vasodilators  [8] . Since PGI 2  
exerts its effects on pulmonary vascular tone via elevation 
of intracellular levels of cyclic adenosine monophosphate 
in the vascular smooth muscle cells, an additional cyclic 
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 Abstract 
 Inhaled prostacyclin (PGI 2 ) aerosol induces selective pul-
monary vasodilation. Further, it improves right ventricu-
lar (RV) function, which may largely rely on pulmonary 
vasodilation, but also on enhanced myocardial contrac-
tility. We investigated the effects of the inhaled PGI 2  an-
alogs epoprostenol (EPO) and iloprost (ILO) on RV func-
tion and myocardial contractility in 9 anesthetized pigs 
receiving aerosolized EPO (25 and 50 ng    kg –1     min –1 ) and, 
consecutively, ILO (60 ng    kg –1     min –1 ) for 20 min each. 
We measured pulmonary artery pressure (PAP), RV 
 ejection fraction (RVEF) and RV end-diastolic-volume 
(RV-EDV), and left ventricular end-systolic pressure-vol-
ume-relation (end-systolic elastance, E es ). EPO and ILO 
reduced PAP, increased RVEF and reduced RVEDV. E es  
was enhanced during all doses tested, which reached 
statistical signifi cance during EPO 25ng  and ILO, but not 
during EPO 50ng . PGI 2  aerosol enhances myocardial con-
tractility in healthy pigs, contributing to improve RV 
function. 
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adenosine monophosphate-mediated positive inotropic 
effect of PGI 2 -analogs has been suggested  [9, 10] . In a re-
cent experimental investigation, we have demonstrated 
that the  intravenous administration of both EPO and ILO 
equally increases left ventricular myocardial contractility 
qualifying PGI 2 -analogs as inodilators  [11] . This effect 
was accompanied by an increase of cyclic adenosine mo-
nophosphate in the interstitial dialysate obtained from 
the apex of the left ventricular wall  [12] . 
 It is, however, still unknown, if such a positive inotro-
pic effect on the heart is also present after  inhalation of 
PGI 2 -analogs in the absence of pulmonary hypertension. 
Therefore, the aim of the present experimental study was 
to test the hypothesis that inhalation of aerosols of the 
PGI 2 -analogs, EPO and ILO in clinically relevant con-
centrations (1) improves right ventricular function and 
(2) that this effect is caused by an improvement of myo-
cardial contractility in vivo. 
 Materials and Methods 
 Study Design 
 The study was approved by the Bavarian Government. It was 
conducted in 9 pigs (German landrace, body weight 30  8 5 kg), 
which were treated and housed in accordance with the ‘Principles 
of Laboratory Animal Care’ (NIH-publication No. 86–23, revised 
version 1985). 
 Anesthesia 
 After one night’s starvation with free access to water, intramus-
cular premedication was performed with midazolam (1 mg    kg –1 ) 
and ketamine (10 mg    kg –1 ). Anesthesia was induced by intravenous 
(i.v.) injection of fentanyl (20   g    kg –1 ) and propofol (2 mg    kg –1 ), 
muscular paralysis by the use of vecuronium (0.4 mg    kg –1  i.v.). All 
animals were placed in supine position and endotracheally intu-
bated. Mechanical ventilation was performed on FiO 2  0.5 to pre-
serve normocapnia (Servo 900 B; Siemens, Solna, Sweden). Bal-
anced anesthesia and muscular paralysis were maintained by the 
inhalation of isofl urane (2–3 vol %) and nitrous oxide (F i NO 2  0.5), 
and by continuous i.v. infusion of fentanyl (40   g    kg –1     h –1  i.v.),
as well as infusion of vecuronium (0.2 mg    kg –1     h –1  i.v.). Normo-
thermia was ensured by means of a warming pad and a warming 
lamp. Insensible fl uid losses were replaced by Ringer solution
(15 ml    kg –1     h –1  i.v.). 
 Surgical Preparation and Instrumentation 
 To minimize the surface of the artifi cial airway and enable ef-
fective inhalation of drug aerosols, we performed tracheostomy in 
all animals. For collection of arterial and mixed-venous blood sam-
ples and for determination of cardiac output using the thermal-dye 
method, a femoral arterial introducer sheath (8.5 F; Arrow, Read-
ing, Pa., USA) and a fast response thermodilution PA catheter (7.5 
F; REF-1 TM , Baxter, Irvine Calif., USA) were inserted. For arterial 
pressure recordings, an aortic tip-manometer catheter (PC 350; 
Millar Instruments, Tex., USA) was placed. For determination of 
myocardial contractility, a combined conductance/tip-manometer 
catheter (7 F, 12 Electrodes; CardioDynamics, Leiden, The Neth-
erlands) and a Fogarty catheter (22 F; Baxter, Irvine, Calif., USA) 
were inserted into the left ventricle and the inferior vena cava, re-
spectively. A central venous catheter (14 G; Arrow) via femoralis 
allowed for continuous drug administration. Catheter positions 
were verifi ed by fl uoroscopy. 
 Interventions and Measurements 
 The instrumentation was followed by a stabilization period of 
30 min. A fi rst set of baseline measurements was obtained thereaf-
ter. We then administered aerosolized EPO (25 and 50 ng    kg –1    
 min –1 ) and ILO (60 ng    kg –1     min –1 ) in consecutive order, over a 
period of 20 min each. EPO and ILO were dissolved in normal sa-
line; the total sodium chloride concentration of the resulting test 
solutions did not differ from isotonic saline. EPO was not abruptly 
withdrawn but slowly tapered down over 30 min. After the termi-
nation of EPO, we allowed for an additional washout period of
30 min ( fi g. 1 ). 
 Aerosol Production, Determination of Droplet Size and Aerosol 
Deposition 
 The PGI 2 -analogs, EPO (Flolan TM , Glaxo-Wellcome, Versailles, 
France) and ILO (Ilomedin TM , Schering, Berlin, Germany) were 
administered with a standard jet nebulizer (Nebulizer 945 TM , Sie-
mens, Erlangen, Germany) in combination with a nebulizer cham-
ber (Micro Cirrus TM , Intersurgical, Wokingham, Berkshire, UK). 
To quantify the amount of aerosol delivery, the exact turnover of 
a test solution in the Micro Cirrus TM  chamber was determined with 
each single drug application and the concentration of the nebulizer 
content was calculated accordingly. In pilot studies, we determined 
the mass median aerodynamic diameter of the aerosol generated 
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protocol as delineated in the text. BL = Baseline. 
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by the Micro Cirrus TM  chamber with a Stoeber centrifuge  [13] and 
determined regional distribution of inhaled particles with a diam-
eter of 1   m using the method described by Hoegl et al.  [14] . An 
aerosol of fl uorescent microspheres (1   m Fluospheres ® ; Molecular 
Probes Europe, Leiden, The Netherlands) was inhaled in an anes-
thetized pig. After sacrifi ce, the lung was removed and dissected 
(264 samples). Regional pulmonary deposition of microspheres was 
calculated from tissue sample fl uorescence, which was measured 
with a luminescence spectrophotometer. Special software was al-
lowed for 3D reconstruction of regional normalized aerosol deposi-
tion (CSD solutions; Oberpfaffenhofen, Germany)  [15] . 
 Measurements 
 A total of three baseline measurements (BL) were performed – 
prior to application of EPO, after tapering of EPO, and after wash-
out prior to ILO. Further measurements were performed after
20-min inhalation of EPO (25 and 50 ng    kg –1     min –1 ) and ILO
(60 ng    kg –1     min –1 ). There was no control measurement after ter-
mination of ILO due to its long half-life time ( fi g. 1 ). 
 Systemic Hemodynamics and Right Ventricular Function 
 Pulmonary arterial pressure was measured with a pulmonary 
artery catheter and a Statham pressure transducer. Left ventricular 
pressure was recorded online at 250 Hz (DasyLab; Datalog, 
Mönchengladbach, Germany) with the conductance/tip-manome-
ter catheter. Cardiac output  [16] , right ventricular ejection fraction 
and end-diastolic volume were determined with fast response ther-
modilution (REF-1 TM  Ejection Fraction/-Cardiac Output Comput-
er; Baxter, Santa Ana, Calif., USA). Central venous pressure (CVP) 
was measured via the proximal catheter lumen. 
 Myocardial Contractility 
 Myocardial contractility was estimated (1) from the fi rst de-
rivative of left ventricular pressure over time and (2) from pressure-
volume loops of the left ventricle, which were registered during a 
preload reduction maneuver during shortly suspended ventilation 
(20 s). When a Fogarty catheter is rapidly infl ated in the vena cava, 
left ventricular volume and pressure decline in a progressive man-
ner. Simultaneously, left ventricular pressure and volume are reg-
istered online at 250 Hz (Meilhaus Electronic, Puchheim, Germa-
ny), allowing establishment of pressure-volume loops for consecu-
tive single heart beats in the presence of progredient unloading. The 
end-systolic points at the end of left ventricular ejection period re-
sult in a straight line, the end-systolic pressure-volume relationship 
(ESPVR). The slope of ESPVR, the end-systolic elastance (E es ), is 
a relatively load independent measure of left  ventricular contractil-
ity. ESPVR and E es  were obtained from calculated left ventricular 
volume derived from the conductance signal (see Appendix). At 
each baseline measurement 5 ml of hypertonic sodium chloride was 
injected to assess parallel conductance at a period of suspended 
ventilation. Estimation of parallel conductance is described in de-
tail elsewhere. Parallel conductance was newly assigned during ev-
ery baseline measurement. During preload reduction, the fi rst three 
beats were excluded (change of parallel conductance by the fi lled 
right ventricle). In absence of ectopic beats, data were accepted. 
Linear regression analysis of the end-systolic points of all beats reg-
istered during preload reduction was performed with a special soft-
ware (Conduct-PC, Version V720.1; CardioDynamics) and the 
slope of ESPVR, E es  was delivered. 
 Blood Samples and Calculations 
 Arterial and mixed-venous blood samples were taken simulta-
neously in air-free syringes, cooled and analyzed instantly in dupli-
cate; pO 2  and pCO 2  were measured with a blood gas analyzer (Chi-
ron Diagnostics, Fernwald, Germany). Hemoglobin concentration 
and hemoglobin O 2  saturation were measured by absorbance spec-
trophotometer (Instrumentation Laboratory, Lexington, Mass., 
USA). Pulmonary shunt fraction and dead space ventilation were 
calculated according to standard formula. 
 Statistics 
 Data are presented as median and semi-interquartile range 
MED (Q3-Q1/2). The three baseline measurements were tested for 
changes over time resulting from the crossover design (rANOVA). 
In each single set of data, the difference between control values and 
values which were obtained during inhalation of EPO and ILO, 
respectively, were calculated. The sum of these differences gener-
ated for one of the test substances was tested with a Signed-Rank 
test. The   -error threshold was set to 5%. 
 Results 
 Aerosol Delivery, Data Acquisition and Stability of 
the Model 
 The mean turnover of the jet nebulizer and the aerosol 
chamber was 0.2 ml    min –1  of test solution at an O 2  fl ow 
rate of 8 liters    min –1 . The MMAD of the aerosol droplets 
denoted 1.1   m with a geometric standard deviation of 
1.6. Tentative nebulization of fl uorescent microspheres 
(1   m) resulted in homogenous regional distribution of 
fl uorescence (  2% deposition, distribution in  fi g. 2 ). In 
9 animals, EPO and ILO were administered. Alterations 
of alveolar ventilation, pulmonary mechanics and gas ex-
change were absent (NS) ( table 1 ). All parameters were 
unchanged during the three baseline measurements 
(NS). 
 Right Ventricular Function 
 We observed a signifi cant reduction of pulmonary ar-
terial pressure during inhalation of low-dose EPO (–13%, 
p  ! 0.05),  high-dose EPO (–12%, p  ! 0.05), and ILO
(–14%, p  ! 0.05). At the same time, right ventricular ejec-
tion fraction increased and right ventricular end-diastol-
ic volume was reduced with high-dose EPO (+16%, p = 
0.05 and –13%, p  ! 0.05) and ILO (+24%, p  ! 0.05 and 
–7%, p  ! 0.05), but not with low-dose EPO (+13% and 
–24%, NS). Right ventricular stroke volume and central 
venous pressure remained unchanged ( table 1 ). 
 Myocardial Contractility 
 Both inhaled EPO and ILO enhanced myocardial con-
tractility in presence of unchanged left ventricular and 
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 Fig. 2. A suspension of fl uorescent microspheres was aerosolized 
and inhaled in a single anesthetized, tracheotomized and mechan-
ically ventilated pig. The fi gure depicts regional deposition distri-
bution of the inhaled microspheres (diameter of 1   m), which was 
obtained ex vivo after sacrifi ce and postmortem removal of the 
whole lung (96 h of drying at CPAP 20 cm H 2 O). The dried lung 
was dissected hierarchically (264 samples). Regional pulmonary 
deposition of microspheres was calculated from tissue sample fl uo-
rescence which was measured automatically with a luminescence 
spectrophotometer (Perkin Elmer). Deposition is expressed by spe-
cifi c fl uorescence per tissue sample weight. Special software allowed 
for three-dimensional reconstruction of the lung. The fi gure depicts 
the normalized regional 3D distribution of microspheres in the re-
constructed lung in false tinting (CSD solutions; Oberpfaffen-
hofen). The color scale illustrates allotment of colors to specifi c 
regional fl uorescence intensity as expressed per sample weight (ar-
bitrary units g –1 ). Distribution of regional microsphere deposition 
was tested in a single pig under the described experimental condi-
tions. All investigated tissue contained fl uorescence. Increased fl u-
orescence was observed in the dorsobasal regions of the lower lobes 
and in the direct neighborhood of the main bronchi. 
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aortic pressure: E es  was enhanced with low-dose EPO (E es  
+18%, p  ! 0.05), but not with high-dose EPO (E es  +13%; 
NS). The increase of E es  was pronounced upon the inhala-
tion of ILO (+64%, p  ! 0.05). Dp/Dt max  increased with 
high-dose EPO (+4%, p 0.05) and with ILO (+6%, p  ! 
0.05), whereas cardiac index improved only slightly after 
ILO (+2%, p  ! 0.05) ( fi g. 3 ,  4 ). 
 Discussion 
 Main Results 
 Recently, we described for the fi rst time the positive 
inotropic effect of intravenous PGI 2  in an in vivo experi-
mental model  [11] , thereby confi rming previous in vitro 
data  [9, 10, 17] . The main novel fi nding of the present 
study is that also  inhalation of the aerosolized PGI 2 - 
analogs EPO and ILO increases myocardial contractility. 
This is of particular signifi cance, since inhalation of PGI 2 -
analogs is the clinically preferred mode of administra-
tion. 
 In the previous i.v. study several concerns had been 
raised, since i.v. EPO induced refl ex tachycardia and hy-
potension. It could not be completely ruled out that the 
observed increase of E es  had been elicited by a humoral 
sympathoadrenergic response to hypotension rather than 
by an intrinsic positive inotropic effect of the prostanoids. 
In the present study, we observed no hypotension, no 
tachycardia or sympathomimetic refl ex, defi nitely sug-
gesting that the signifi cant increase of E es  refl ects a true 
increase in contractility upon inhaled EPO and ILO. In 
addition, the new data show that the positive inotropic 
effect is independent of the route of administration. 
 Mechanism of Action 
 There are two main mechanisms which could explain 
a positive inotropic effect of inhaled PGI 2 -analogs. First, 
pharmacologically active PGI 2  might reach the left ven-
tricular myocardium via ‘spill over’ to the systemic cir-
culation  [18] and might directly act on the cardiomyo-
cyte. Systemic effects after spill over of inhaled PGI 2  have 
been previously reported  [6, 19] . A direct action of EPO 
and ILO on the cardiomyocyte could result from activa-
tion of a PGI 2  receptor that interacts with adenylate cy-
clase. Both, EPO and ILO, are binding to myocardial 
prostaglandin receptors (EP 3 ) and do inhibit adenylate 
BL 1 EPO25 ng EPO50 ng BL 3 ILO
HR, min–1 117815 11487 11384 123821 122818
CI, min–1  m–2 4.680.8 4.281.0 4.480.8 5.681.0 5.780.7
MAP, mm Hg 11189 11089 109810 99812 10189
LVEDV, ml 38811 54813 47812 45816 44816
CPP, mm Hg 6889 7088 64812 5787 5887
PAP, mm Hg 2882 2583‡ 2583‡ 2985 2483‡
RVEF, % 3184 3585 36830.05 3483 4284‡
RVEDV, ml 9880 9283 6885‡ 113825 105820‡
CVP,mm Hg 982 1182 1181 1283 1282
RVSV, ml 3788 3783 3986 4088 44811
AWPpeak mm Hg 3483 3482 3282 3284 3285
TV, ml 289847 311832 311832 271832 260893
Vd/Vt, % 1885 1284 1484 18811 2183
QsQt, % 2483 2581 2683 2681 3183
PaCO2, Torr 3781 3784 3784 3783 4083
PaO2, Torr 199841 187835 161837 159826 154832
All values are given as median 8 semi-interquartile range MED 8 (Q3-Q1)/2.
HR = Heart rate; CI = cardiac index; MAP = mean arterial pressure; LVEDV = left 
ventricular end-diastolic volume; CPP = coronary perfusion pressure; PAP = pulmonary 
arterial pressure; RVEF = right ventricular ejection fraction; RVEDV = right ventricular 
end-diastolic volume; CVP = central venous pressure; RVSV = right ventricular stroke 
volume; AWPpeak = peak airway pressure;  TV = tidal volume; VdVt = dead space ventila-
tion; QsQt = pulmonary shunt fraction; PaCO2 = arterial carbon dioxide partial pressure; 
PaO2 = arterial oxygen partial pressure.
‡ p < 0.05 versus previous time point of measurement.
 
 
 Table 1. Cardiovascular and respiratory
parameters 
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cyclase of the sarcolemma in the myocytes. Since experi-
mental administration of ß-blockers in isolated ventricles 
was shown to notably reduce the positive inotropic effects 
of PGI 2   [17] , PGI 2  might also exert part of its inotropic 
action via ß-receptors, which are also located on the sur-
face of the myocytes. 
 Alternatively, the positive inotropic action of PGI 2  
might result from a nerve stimulus generated locally in 
the lung in afferent autonomic sympathic nervous fi bers. 
The positive inotropic effect on the cardiomyocyte would 
fi nally be exerted via an efferent neuron as an autonomic 
nervous refl ex  [1] . Paradoxical tracheal constriction, as 
observed upon PGI 2  inhalation in dogs, is mediated by 
autonomic refl ex activity via slow afferent nerval struc-
tures (C fi bers) in the terminal airways  [20] . In analogy, 
the positive inotropic action might rely on such refl ex ac-
tivity. At present, the detailed mechanism remains to be 
elucidated. 
 
 Aerosol Delivery and Deposition 
 Since a jet nebulizer was used, respiratory volumes had 
to be adjusted to maintain airway pressures. However, 
our data show, that neither alveolar ventilation, nor oxy-
genation, nor pulmonary mechanics were affected by this 
fact. Aerosol production with our setup was in the range 
of what has previously been reported in experimental and 
clinical studies with jet and ultrasound nebulizers  [6, 21] . 
Using the Stoeber centrifuge we give evidence that our 
aerosol droplets (MMAD 1.1   m) are likely to deposit in 
the alveolar region  [22] . Moreover, as predicted by 
MMAD, homogenous regional distribution of particle de-
position approximating a diameter of 1   m was con-
fi rmed by fl uorescence measurements and reconstruction 
of the lung, as depicted in  fi gure 2 . 
 Measurement of Myocardial Contractility 
 Changes in the slope of the end-systolic pressure rela-
tionship (E es ) are load independent over a large range of 
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 Fig. 3. Depiction of two original registrations of left ventricular 
pressure (LVP, y-axis) plotted against left ventricular volume (x-
axis) during two preload reduction maneuvers: at baseline (BL, left 
panel) and during inhalation of iloprost-trometamol (ILO, 60 ng   
 kg –1     min –1 , right panel). During each maneuver, a Fogarty balloon 
catheter is infl ated in the inferior caval vein. The maneuver encom-
passes approximately 20 complete heart cycles. Every single pres-
sure-volume-loop represents a single heart cycle with diastolic fi ll-
ing, systolic isovolumetric pressure increase, systolic ejection and 
diastolic relaxation of the left ventricle. During the maneuver, left 
ventricular end-systolic pressure and volume are progrediently re-
duced, the pressure-volume-loops shrink and shift to the left. If the 
end-systolic points of every single heart cycle are connected, they 
give a straight line. The straight line is defi ned as end-systolic pres-
sure volume relation (ESPVR). The slope of this relation is defi ned 
as end-systolic elastance (E es ) and is a close estimation of load in-
dependent left ventricular contractility. In the depicted single ex-
periment, end-systolic elastance increases notably from 4.72 to 6.00 
ml    mm Hg –1  during inhalation of iloprost-trometamol (ILO). 
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 Fig. 4. Depiction of  changes in end-systolic elastance (E es ) ( a ) and 
maximum of the fi rst derivative of left ventricular pressure over 
time (Dp/Dt max ) ( b ) as well as left ventricular systolic pressure ( c ) 
as measures of myocardial contractility during inhalation of epo-
prostenol (EPO, 25 and 50 ng    kg –1     min –1 ) and iloprost-trometamol 
(ILO, 60 ng    kg –1     min –1 ). Each graphic gives data from all single 
experiments as well as box-and-whisker plots. The boxes depict 
median, fi rst and third interquartile, the whiskers 10th and 90th 
percentile. Changes as compared to baseline are indicated by a 
double dagger; the   -error threshold is set to 0.05; Wilcoxon Signed-
Rank Test. The graphic depicts an improvement in all load-depen-
dent and independent measures of ventricular performance and 
contractile myocardial force during inhalation of prostacyclin 
(PGI 2 ) analogs.  ‡  p  ! 0.05 versus baseline (BL). 
 Kemming et al. 
 
 Eur Surg Res 2005;37:9–17 16
left ventricular pre- and afterload  [23] . E es  thereby refl ects 
the mechanical properties of the left ventricle in the state 
of complete contraction at the end of systole. To obtain 
valid information from E es  on the contractile state of the 
myocardium, ESPVR has to be linear. Yet, ESPVR may 
be nonlinear at extreme loading conditions  [24] . Since 
ESPVR was nonlinear in the very beginning and at the 
end of preload reduction in our study, we excluded the 
fi rst three beats and restricted data recording to the pe-
riod of simultaneous constant pressure and volume de-
crease. This procedure resulted in very high data quality 
(mean r 2  of ESPVR 0.99 in 12  8 6 beats), thereby ensur-
ing linearity of ESPVR in our experiments. 
 Furthermore, tachycardia may hamper valid determi-
nation of E es . Yet, changes in heart rate were absent in 
our study. Moreover, a reduction of aortic impedance has 
been shown to affect E es   [24] . Yet, neither mean arterial 
pressure nor arterial elastance as a measure of vascular 
load were changed throughout our experiments, suggest-
ing that measured data of E es  are valid. Like others  [25] , 
we occasionally observed negative intercepts of ESPVR. 
This phenomenon may relate to the fact that absolute 
stroke volume was not referenced to a second method in 
our study. It may further relate to the loading range of the 
ventricle and to the calibration of the conductance signal. 
One point calibration of the parallel conductance by hy-
pertonic saline is only an approximation, since parallel 
conductance may vary over time. However, the number 
of repeated saline injections has to be restricted in a single 
experiment to avoid increases in arterial sodium concen-
tration. Therefore, parallel conductance was determined 
only with baseline measurements in our experiments. 
Changes in sodium concentrations were minimal, and 
interference of sodium concentration with contractility, 
therefore, is unlikely. Present baseline data corroborate 
previous work from our group in pigs and dogs  [11, 26] . 
 We describe an increase of load-independent contrac-
tility upon inhaled PGI 2 -analogs. Of note, we observed a 
signifi cant increase of E es  with low-dose EPO and with 
ILO, but not with high dose EPO. The reason for this 
fi nding is unclear. However, this does not question the 
proof of concept, since we observed positive inotropism 
after both inhaled EPO and ILO (including a nonsignifi -
cant trend towards increased E es  with high-dose EPO). 
We assume that the large scatter of our data explains this 
inconsistency. 
 Study Design 
 We investigated both inhaled EPO and ILO in the same 
experimental setup intending to reduce the number of lab-
oratory animals. Theoretically, the effects of the investi-
gated drugs might overlap. However, half-life time of EPO 
is short (2–3 min). Baseline measurements were performed 
prior to EPO, after tapering of EPO and after washout 
prior to administration of ILO. All parameters investigat-
ed during BL 1, 2, and 3 were tested to exclude overlap 
effects (rANOVA; NS; data not shown). We did not ran-
domize the interventions, since administration of ILO pri-
or to EPO is not feasible due to the longer half-life time of 
ILO (elimination half-life time 20–30 min, half-life of ef-
fects 60 min). Intentionally, we investigated the effects of 
inhaled EPO and ILO on right ventricular function in the 
absence of pulmonary hypertension, because we aimed to 
characterize the effects of the PGI 2 -analogs in the healthy 
heart. Clearly, further studies are required to re-evaluate 
the effects of inhaled prostanoids on contractility also un-
der conditions of severe pulmonary hypertension. 
 Choice of Administered Dose 
 In the present study, changes in myocardial contractil-
ity were observed in a clinically relevant range of dosages 
of EPO and ILO. In the literature, EPO has been used in 
dosages ranging from 3 to 100 ng kg –1  min –1 . ILO is ad-
ministered at a dose of 5–20   g, equaling 15–60 ng kg –1  
min –1 , leaving the nebulizer over a period of 20 min  [1, 
27] . Since a threshold dose at which to expect signifi cant 
positive inotropism was not known, we did not investi-
gate less than 25 ng kg –1  min –1  EPO or 20   g ILO. Estab-
lishment of a dose-response relationship of the inotropic 
effect is nevertheless desirable. 
 Conclusion 
 Our data give evidence that inhaled EPO and ILO in-
crease myocardial contractility in vivo, suggesting an ino-
dilatory effect of PGI 2 -analogs which is independent of 
the route of administration. An additional positive ino-
tropic effect may contribute to the benefi cial effects ob-
served during short-term and long-term use of inhaled 
PGI 2 -analogs in patients. In the future, inhaled PGI 2 -an-
alogs should be considered as inodilators rather than pure 
pulmonary vasodilators. 
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 Appendix 
 Equation 1: body surface area according to Holt et al.  [16] 
 BSA =  k    BW 2/3 ; ( k = 9) 
 BSA: body surface area; k: constant for landrace pigs; BW: body 
weight. 
 Equation 2: Left ventricular volume at time t, V(t) 
 V ( t ) =      L 2    G n ( t ) –       L 2   G  
 V(t): volume at time t;   : calibration factor for blood conductivity; 
G n (t): Conductance of one catheter segment at time t, where n =
(1, …, 4, 5) including only segments of the catheter which were 
placed in the left ventricle as indicated by segmental signals; G   : 
parallel conductance of the surrounding tissue. 
 Equation 3: Coronary perfusion pressure 
 CPP  ( mm Hg ) =  AOP diast – LVEDP 
 CPP: coronary perfusion pressure; AOP diast: diastolic aortic pres-
sure; LVEDP: left ventricular end-diastolic pressure. 
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